Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Windtree Therapeutics Inc
(NQ:
WINT
)
0.3601
-0.0099 (-2.68%)
Streaming Delayed Price
Updated: 2:24 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
25,233
Open
0.3600
Bid (Size)
0.3601 (1)
Ask (Size)
0.3679 (8)
Prev. Close
0.3700
Today's Range
0.3499 - 0.3679
52wk Range
0.2820 - 18.48
Shares Outstanding
5,148,219
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 02, 2024
Via
Benzinga
Windtree Therapeutics – This Biotech Inks License Deal For Lead Candidate
January 29, 2024
Craig Fraser, CEO of Windtree Therapeutics, Inc. (NASDAQ: WINT), was recently interviewed by Benzinga. Windtree is advancing late-stage interventions for cardiovascular disorders to treat patients in...
Via
Benzinga
Performance
YTD
-48.42%
-48.42%
1 Month
+9.79%
+9.79%
3 Month
-50.66%
-50.66%
6 Month
-64.35%
-64.35%
1 Year
-92.19%
-92.19%
More News
Read More
Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company
January 26, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Thursday's After-Market Session
January 25, 2024
Via
Benzinga
Windtree Therapeutics (NASDAQ: WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company
January 25, 2024
Via
Benzinga
Week in Review: Lee’s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy
January 20, 2024
Via
Talk Markets
12 Health Care Stocks Moving In Friday's After-Market Session
January 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
January 18, 2024
Via
Benzinga
Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China
January 18, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 17, 2024
Via
Benzinga
Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China
January 17, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 17, 2024
Via
Benzinga
Windtree Therapeutics Announces Reduction In Arrhythmias In A New Study With Istaroxime And A Pure SERCA2a Activator
January 03, 2024
Via
Benzinga
Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024
December 19, 2023
Via
ACCESSWIRE
Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected mid-2024
December 18, 2023
Via
Benzinga
Why Immunic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
October 10, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
October 10, 2023
Via
InvestorPlace
Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session
October 09, 2023
Via
Benzinga
Windtree Therapeutics (NASDAQ:WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market
August 16, 2023
Via
ACCESSWIRE
Windtree Therapeutics (NASDAQ: WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market
August 15, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
September 21, 2023
Via
Benzinga
How Windtree Therapeutics (NASDAQ: WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators
August 15, 2023
Via
Benzinga
Windtree Therapeutics' (NASDAQ: WINT) Upcoming Istaroxime Development Milestones And Next Generation Drug Candidates Could Produce New Fast Follow-On Line Of Drugs For Heart Failure
July 25, 2023
Via
ACCESSWIRE
Windtree Therapeutics' (NASDAQ: WINT) Upcoming Istaroxime Development Milestones And Next Generation Drug Candidates Could Produce New Fast Follow-On Line Of Drugs For Heart Failure
July 24, 2023
Via
Benzinga
The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market
July 18, 2023
Via
ACCESSWIRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.